Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CAPRICOR THERAPEUTICS, INC.CAPR · Entity 5337 | Director | February 21, 2023 | February 23, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CAPRICOR THERAPEUTICS, INC.
Report date February 21, 2023 · Filed February 23, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,147 |
Ending reported balance
After 2023-02-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-21 · Exercise / conversion · Acquired 1,401 · Balance 62,599 Row 2 · 2023-02-21 · Disposition to issuer · Disposed 452 · Balance 62,147 F1: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on February 21, 2023 of $4.31. The options would otherwise expire on February 22, 2023, pursuant to their terms. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.39 · Expires 2023-04-22 | Direct | 0 |
Reported balance
After 2023-02-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-02-21 · Exercise / conversion · Disposed 1,401 · Balance 0 F2: This option was granted on February 22, 2013 and was previously reported as covering 14,015 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. F3: 25% of the shares vested immediately, with the remainder vesting monthly over 36 months commencing May 1, 2013. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on February 21, 2023 of $4.31. The options would otherwise expire on February 22, 2023, pursuant to their terms.
F2: This option was granted on February 22, 2013 and was previously reported as covering 14,015 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
F3: 25% of the shares vested immediately, with the remainder vesting monthly over 36 months commencing May 1, 2013.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2023 Filed Feb 23, 2023 14:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,401 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001415889-23-003084 · form4-02232023_090208.xml · derivative · entry 3 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,401 shares Expires 2023-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was granted on February 22, 2013 and was previously reported as covering 14,015 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. F3 · derivative.exercise_date: 25% of the shares vested immediately, with the remainder vesting monthly over 36 months commencing May 1, 2013. F2 · derivative.underlying_shares: This option was granted on February 22, 2013 and was previously reported as covering 14,015 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 14:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerCommon Stock | 452 | $4.31 | $1,948.12 |
DisclosureSEC source: 0001415889-23-003084 · form4-02232023_090208.xml · nonDerivative · entry 2 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,147 F1 · date: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on February 21, 2023 of $4.31. The options would otherwise expire on February 22, 2023, pursuant to their terms. F1 · price: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on February 21, 2023 of $4.31. The options would otherwise expire on February 22, 2023, pursuant to their terms. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 14:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 1,401 | $1.39 | $1,947.39 |
DisclosureSEC source: 0001415889-23-003084 · form4-02232023_090208.xml · nonDerivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:01 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001415889-23-000595 · form4-01052023_080148.xml · derivative · entry 3 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2033-01-03 F3 · derivative.exercise_date: The shares of the award are fully vested and exercisable as of January 3, 2023, the date of the grant. The award pertains to annual board service. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:01 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 7,120 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001415889-23-000595 · form4-01052023_080148.xml · derivative · entry 2 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,120 Underlying: Common Stock · 7,120 shares Expires 2033-01-03 F2 · derivative.exercise_date: The shares of the award are fully vested and exercisable as of January 3, 2023, the date of the grant. The award pertains to annual board committee service. Read SEC document |
| January 03, 2023 Filed Jan 6, 2023 01:01 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 37,770 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001415889-23-000595 · form4-01052023_080148.xml · derivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,770 Underlying: Common Stock · 37,770 shares Expires 2033-01-03 F1 · derivative.exercise_date: The shares vest 1/12th of the first day of each month, commencing February 1, 2023, with the last month vesting on December 31, 2023, until the stock option becomes fully vested and exercisable. The award pertains to annual board service. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,449 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001415889-22-003580 · form4-04012022_050408.xml · derivative · entry 4 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,449 shares Expires 2022-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: This option was granted on April 27, 2012 and was previously reported as covering 124,491 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. F5 · derivative.exercise_date: The shares vested immediately. F4 · derivative.underlying_shares: This option was granted on April 27, 2012 and was previously reported as covering 124,491 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,455 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001415889-22-003580 · form4-04012022_050408.xml · derivative · entry 3 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,455 shares Expires 2022-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: This option was granted on April 27, 2012 and was previously reported as covering 154,555 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. F3 · derivative.exercise_date: The shares vested 1/48th of the first day of each month, commencing May 1, 2012. F2 · derivative.underlying_shares: This option was granted on April 27, 2012 and was previously reported as covering 154,555 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Tax withholdingCommon Stock | 11,309 | $3.43 | $38,789.87 |
DisclosureSEC source: 0001415889-22-003580 · form4-04012022_050408.xml · nonDerivative · entry 2 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,595 F1 · kind: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on March 31, 2022 of $3.43. The options would otherwise expire on April 27, 2022, pursuant to their terms. F1 · price: Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on March 31, 2022 of $3.43. The options would otherwise expire on April 27, 2022, pursuant to their terms. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 21:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 27,904 | $1.39 | $38,786.56 |
DisclosureSEC source: 0001415889-22-003580 · form4-04012022_050408.xml · nonDerivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 83,590 | $0.00 Strike: $3.18 | $0.00 |
DisclosureSEC source: 0001415889-22-000280 · form4-01042022_090134.xml · derivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,590 Underlying: Common Stock · 83,590 shares Expires 2032-01-03 F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2022, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:04 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 72,066 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001104659-21-001593 · tm211849-7_4seq1.xml · derivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,066 Underlying: Common Stock · 72,066 shares Expires 2031-01-04 F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing February 1, 2021, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| September 24, 2020 Filed Sep 28, 2020 12:30 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,299 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001104659-20-109138 · tm2031826-1_4.xml · derivative · entry 3 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,299 shares Expires 2020-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: This option was previously reported as covering 82,994 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019. F4 · derivative.exercise_date: 4,409 of the shares of common stock subject to this option vested immediately. 778 of the shares of common stock subject to this option vested on each of October 31, 2010, January 31, 2011, April 30, 2011, July 31, 2011, and October 31, 2011. F3 · derivative.underlying_shares: This option was previously reported as covering 82,994 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019. Read SEC document |
| September 24, 2020 Filed Sep 28, 2020 12:30 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 8,299 | $3.70 | $30,706.30 |
DisclosureSEC source: 0001104659-20-109138 · tm2031826-1_4.xml · nonDerivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On September 24, 2020, the Reporting Person exercised stock options for 8,299 shares of Common Stock. The exercise price of $3.70 per share and the exercise was subject to the terms and conditions of a Stock Option Award which was granted on September 25, 2010 under the Issuer's 2006 Stock Option Plan. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:35 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 83,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001104659-20-071423 · tm2022128-7_4.xml · derivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2030-06-05 F1 · derivative.exercise_date: The shares vest 1/48th of the first day of each month, commencing March 1, 2020, until the stock option becomes fully vested and exercisable. The following stock option grant was approved by the Board on February 12, 2020 under the 2020 Plan, contingent upon stockholder approval of the 2020 Plan, which was obtained on June 5, 2020. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Issuer if the reporting person's service to the Issuer terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 27,904 | Not disclosed Strike: $3.70 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 14 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,904 shares Expires 2022-04-27 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,401 | Not disclosed Strike: $3.70 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 13 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,401 shares Expires 2023-03-06 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,500 | Not disclosed Strike: $57.80 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 12 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2025-03-03 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,000 | Not disclosed Strike: $31.20 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 11 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2026-06-02 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,356 | Not disclosed Strike: $25.50 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 10 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,356 shares Expires 2027-01-03 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F4 · derivative.exercise_date: 856 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The remaining 1,500 shares will vest 1/12th on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,550 | Not disclosed Strike: $15.70 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 9 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,550 shares Expires 2028-01-02 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F3 · derivative.exercise_date: 1,050 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 1,500 shares will vest 1/12th on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,500 | Not disclosed Strike: $3.25 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 8 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires 2029-08-08 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F1 · derivative.exercise_date: 3,000 of the shares were vested on the date of grant. The remaining 1,500 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 27,904 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 7 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,904 Underlying: Common Stock · 27,904 shares Expires 2022-04-27 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 1,401 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 6 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,401 Underlying: Common Stock · 1,401 shares Expires 2023-03-06 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 1,500 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 5 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2025-03-03 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 3,000 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 4 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2026-06-02 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F5 · derivative.exercise_date: The stock option award is fully vested and exercisable. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 2,356 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 3 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,356 Underlying: Common Stock · 2,356 shares Expires 2027-01-03 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F4 · derivative.exercise_date: 856 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The remaining 1,500 shares will vest 1/12th on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 2,550 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 2 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,550 Underlying: Common Stock · 2,550 shares Expires 2028-01-02 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F3 · derivative.exercise_date: 1,050 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 1,500 shares will vest 1/12th on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:08 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (Right to Buy) · Derivative | 4,500 | Not disclosed Strike: $1.39 | Not disclosed |
DisclosureSEC source: 0001104659-20-022104 · tm208086d7_4.xml · derivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2029-08-08 F2 · price: The reported transactions involved the repricing of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of replacement options, with a new exercise price of $1.39 per share. F1 · derivative.exercise_date: 3,000 of the shares were vested on the date of grant. The remaining 1,500 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. The option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| December 17, 2019 Filed Dec 20, 2019 00:34 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantWarrants (Right to Buy) · Derivative | 20,391 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001104659-19-074513 · tm1926719d1_4.xml · derivative · entry 3 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,391 Underlying: Common Stock · 20,391 shares Expires 2024-12-17 F1 · price: The Reporting Person on December 17, 2019, purchased 20,391 shares of the common stock of Capricor Therapeutics, Inc. (the "Issuer"), and accompanying amount of warrants to purchase up to an aggregate of 20,391 shares of the Issuer's common stock, at a combined purchase price of $1.226 per share of common stock and accompanying warrant, for a total cost of approximately US$25,000. Read SEC document |
| December 17, 2019 Filed Dec 20, 2019 00:34 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantCommon Stock | 20,391 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-074513 · tm1926719d1_4.xml · nonDerivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,304 F1 · price: The Reporting Person on December 17, 2019, purchased 20,391 shares of the common stock of Capricor Therapeutics, Inc. (the "Issuer"), and accompanying amount of warrants to purchase up to an aggregate of 20,391 shares of the Issuer's common stock, at a combined purchase price of $1.226 per share of common stock and accompanying warrant, for a total cost of approximately US$25,000. Read SEC document |
| August 08, 2019 Filed Aug 10, 2019 01:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0001144204-19-038996 · tv527327_form4.xml · derivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2029-08-08 F1 · derivative.exercise_date: 3,000 of the shares shall vest immediately. The remaining 1,500 shares will vest 1/48th on the first day of each month, commencing September 1, 2019, until the stock option becomes fully vested and exercisable. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:03 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 25,500 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0001144204-18-000863 · tv482720_4.xml · derivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 25,500 shares Expires 2028-01-02 F1 · derivative.exercise_date: 10,500 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2018, until the stock option becomes fully vested and exercisable. The remaining 15,000 shares will vest 1/12 on the first day of each month, commencing February 1, 2018, with the last month vesting on December 31, 2018. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 16:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionStock Option (right to buy) · Derivative | 20,748 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001144204-17-053990 · tv477689_4.xml · derivative · entry 3 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,748 shares Expires 2017-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the Reporting Person's stock option became exercisable on each of the following dates: (1) February 1, 2008; (2) May 1, 2008; (3) August 1, 2008; and (4) November 1, 2008. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 16:00 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | Exercise / conversionCommon Stock | 20,748 | $0.16 | $3,319.68 |
DisclosureSEC source: 0001144204-17-053990 · tv477689_4.xml · nonDerivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On October 23, 2017, the Reporting Person exercised stock options for 20,748 shares of Common Stock. The exercise price was $0.16 per share and the exercise was subject to the terms and conditions of a Stock Option Award which was granted on November 1, 2007 under the Company's 2006 Stock Option Plan. Read SEC document |
| May 09, 2017 Filed May 11, 2017 18:31 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | PurchaseCommon Stock | 10,000 | $3.10 | $31,000.00 |
DisclosureSEC source: 0001144204-17-026396 · v466673_4.xml · nonDerivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,384 F1 · kind: The Reporting Person entered into a Subscription Agreement with Capricor Therapeutics, Inc. (the "Issuer") pursuant to which the Reporting Person, on May 5, 2017 purchased an aggregate of 10,000 shares of the Issuer's common stock at a purchase price of $3.10 per share for total cash proceeds of approximately US$31,000. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 02:45 UTC | CAPRICOR THERAPEUTICS, INC. CAPR · Entity 5337 | GrantStock Option (right to buy) · Derivative | 23,560 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001144204-17-000706 · v456182_4.xml · derivative · entry 1 Manzo Louis · CIK 0001593100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,560 Underlying: Common Stock · 23,560 shares Expires 2027-01-03 F1 · derivative.exercise_date: 8,560 of the shares will vest 1/48th on the first day of each month, commencing February 1, 2017, until the stock option becomes fully vested and exercisable. The remaining 15,000 shares will vest 1/12 on the first day of each month, commencing February 1, 2017, with the last month vesting on December 31, 2017. However, the option is subject to early exercise and, therefore, all or any part of the option can be exercised at any time. If the reporting person elects to take advantage of the early exercise feature and purchase shares prior to the vesting of such shares, the shares will be deemed restricted stock and will be subject to a repurchase option in favor of the Registrant if the reporting person's service to the Registrant terminates prior to vesting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.